Related Experiment Video
Updated: Jan 10, 2026
Noninvasive Monitoring of Lesion Size in a Heterologous Mouse Model of Endometriosis
Published on: February 26, 2019
Diagnostic accuracy of non-coding RNA for detecting endometriosis: A systematic review and meta-analysis
Seyed Danial Mohammadi1, Abasali Keshtkar2, Ashraf Moini3
1Anatomy Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Objectives:
Endometriosis diagnosis currently relies on invasive laparoscopy, creating a need for non-invasive alternatives. This study evaluates microRNAs (miRNAs) as potential diagnostic biomarkers for endometriosis through systematic evidence synthesis and performance analysis.
Methods:
We systematically reviewed studies (1992-2025) from seven databases (Pub-Med/MEDLINE, Web of Science, Scopus, etc.) using endometriosis- and ncRNA-related keywords.
Included Studies:
(1) used qRT-PCR for miRNA/lncRNA detection, (2) con-firmed endometriosis via laparoscopy, and (3) provided data to construct 2 × 2 contingency tables. All human biospecimens were eligible; no restrictions were applied to study design or language. Exclusions included non-RNA biomarkers or non-PCR methods. QUADAS-1 assessed methodological quality. To avoid multiplicity, diagnostic accuracy metrics (sensitivity, specificity) were calculated and synthesized separately for each biomarker. Evidence certainty was evaluated with GRADE.
Results:
Among 28 qualifying studies (most with QUADAS-1 scores ≥7), mir-8 showed optimal accuracy (sensitivity: 94.8 %, 95 % CI 58.0-99.6 %; specificity: 91.9 %, 95 % CI 71.7-98.1 %) with favorable likelihood ratios (PLR > 5, NLR < 0.2), albeit with significant het-erogeneity (I2 > 90 %). mir - 122 demonstrated more consistent performance with narrower confidence intervals.
Conclusions:
While mir-8 exhibits superior diagnostic accuracy, mir - 122 expression must be validated in a patient cohort to underline its clinical utility. However, current evidence remains limited by low GRADE certainty. Our findings highlight two critical considerations for biomarker development: (1) the necessity of evaluating methodological quality and heterogeneity along-side traditional metrics, and (2) the distinct diagnostic profiles of individual miRNAs, which preclude combination approaches. These results emphasize the need for standardized, independent validation of candidate miRNAs before clinical implementation.
